Marla L. Watt

发表

PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease

Manuel B. Graeber, Howard J. Federoff, Aron C. Eklund, 2010, Science Translational Medicine.

A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy

Dawn M. Toolan, Monika Kandebo, Sean M. Smith, 2021, Neurobiology of Disease.

Characterization of PCS1055, a novel muscarinic M4 receptor antagonist.

C. Felder, C. H. Croy, Marla L. Watt, 2016, European journal of pharmacology.

The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation

Laura A. Struzyna, Marla L. Watt, L. Struzyna, 2021, Molecular Pharmacology.

The Muscarinic Acetylcholine Receptor Agonist BuTAC Mediates Antipsychotic-Like Effects via the M4 Subtype

D. McKinzie, C. Felder, L. Rorick-Kehn, 2013, Neuropsychopharmacology.

Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist

S. Hitchcock, D. McKinzie, Bin Liu, 2011, Journal of Pharmacology and Experimental Therapeutics.

Design and synthesis of N-[6-(Substituted Aminoethylideneamino)-2-Hydroxyindan-1-yl]arylamides as selective and potent muscarinic M₁ agonists.

S. Hitchcock, F. Bymaster, B. Liu, 2015, Bioorganic & medicinal chemistry letters.

Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain

E. Nisenbaum, D. McKinzie, C. Felder, 2017, Journal of Pharmacology and Experimental Therapeutics.

Translational pharmacology of the mGluR 2-preferring agonist LY 2812223 in animal and human brain

E. Nisenbaum, D. McKinzie, C. Felder, 2017 .

Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist

S. Hitchcock, D. McKinzie, Bin Liu, 2011, Journal of Pharmacology and Experimental Therapeutics.